Immunovant discontinued IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus after a Phase 2 setback, the company said. The decision closes one pathway for the anti-FcRn antibody approach and narrows near-term options for FcRn-focused autoimmune development. The move follows the same clinical program named by Roivant as IMVT-1402, where Roivant previously reported Phase 2b failure in lupus—highlighting how FcRn antibody strategies can face efficacy hurdles even with a strong mechanistic rationale. For biotech planning, the termination is a reminder that mechanism-driven programs still require durable, clinically meaningful biomarker and symptom improvements across patient subsets. It also alters the competitive landscape for anti-FcRn immunology assets. Investors will likely watch whether other FcRn competitors can demonstrate differentiated clinical profiles that translate into registrational-grade results.